Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06298565 · ClinicalTrials.gov registry record

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

A clinical trial of Myasthenia Gravis, sponsored by argenx.

Recruiting
Registry status
680
Enrollment target
20
Study locations

NCT06298565 is a study of Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 680 participants, above the 170-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (300% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06298565, a study of Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.

RECRUITING
Registry status
680 participants
Enrollment target
20
Study locations

Study Summary

This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.

Conditions Studied

Myasthenia Gravis

Interventions

  • BIOLOGICAL efgartigimod

Study Locations (20)

Florida

  • SFM Clinical Research, LLC - Boca Raton
  • University of Florida College of Medicine Jacksonville - Jacksonville Beach
  • Medsol Clinical Research Center Inc - Port Charlotte
  • BayCare Health System, Inc. St Anthony's Hospital - St. Petersburg

Other

  • Kepler Universitätsklinikum, Universitätsklinik für Neurologie, Med Campus III - Linz
  • UZ Leuven (University Hospitals Leuven) - Leuven
  • Klinikum Altenburger Land GmbH - Altenburg

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Oregon

  • Oregon Health and Science University - Portland
  • University of Colorado Hospital - Portland

California

  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center, - San Francisco

Illinois

  • Prairie Education and Research Cooperative and HSHS Medical Group - O'Fallon

Iowa

  • University of Iowa - Iowa City

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 680 participants
Start Date 2024-11-04
Est. Completion 2034-06

Sponsor

argenx

49 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06298565

The ClinicalTrials.gov registry entry for NCT06298565 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 170-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (300% higher). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which efgartigimod is the first listed.

NCT06298565 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Other, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06298565 about?

NCT06298565 is a clinical study titled "A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa". This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who...

What is the current status of trial NCT06298565?

This trial is currently recruiting. The enrollment target is 680 participants. The study started on 2024-11-04. Estimated completion is 2034-06.

What conditions does trial NCT06298565 study?

This clinical trial studies the following conditions: Myasthenia Gravis.

What interventions are being tested in trial NCT06298565?

The interventions under investigation include: efgartigimod (BIOLOGICAL).

Who is sponsoring clinical trial NCT06298565?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06298565 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myasthenia Gravis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.